Insider Selling: Intercept Pharmaceuticals Inc (ICPT) Insider Sells 2,000 Shares of Stock

Share on StockTwits

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $111.51, for a total transaction of $223,020.00. Following the completion of the sale, the insider now directly owns 42,543 shares of the company’s stock, valued at approximately $4,743,969.93. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

David Shapiro also recently made the following trade(s):

  • On Friday, January 4th, David Shapiro sold 474 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $97.48, for a total transaction of $46,205.52.
  • On Wednesday, January 2nd, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $98.28, for a total transaction of $196,560.00.
  • On Monday, December 17th, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $106.62, for a total transaction of $213,240.00.

Shares of Intercept Pharmaceuticals stock opened at $91.83 on Friday. The firm has a market capitalization of $2.94 billion, a P/E ratio of -6.39 and a beta of 1.88. The company has a quick ratio of 5.98, a current ratio of 5.98 and a debt-to-equity ratio of 3.83. Intercept Pharmaceuticals Inc has a fifty-two week low of $58.03 and a fifty-two week high of $133.74.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. Leerink Swann downgraded shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday. JMP Securities boosted their price objective on shares of Intercept Pharmaceuticals from $175.00 to $200.00 and gave the company an “in-line” rating in a research report on Wednesday. Cantor Fitzgerald reissued a “buy” rating and set a $170.00 price objective on shares of Intercept Pharmaceuticals in a research report on Tuesday. Finally, ValuEngine downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $150.79.

A number of institutional investors have recently modified their holdings of ICPT. Vanguard Group Inc lifted its stake in Intercept Pharmaceuticals by 2.8% in the 3rd quarter. Vanguard Group Inc now owns 1,952,931 shares of the biopharmaceutical company’s stock worth $246,772,000 after purchasing an additional 54,038 shares in the last quarter. Strs Ohio grew its holdings in Intercept Pharmaceuticals by 30.0% during the 4th quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 300 shares during the last quarter. Macquarie Group Ltd. grew its holdings in Intercept Pharmaceuticals by 158.8% during the 3rd quarter. Macquarie Group Ltd. now owns 35,561 shares of the biopharmaceutical company’s stock valued at $4,493,000 after purchasing an additional 21,819 shares during the last quarter. AQR Capital Management LLC bought a new position in Intercept Pharmaceuticals during the 3rd quarter valued at about $2,764,000. Finally, FMR LLC grew its holdings in Intercept Pharmaceuticals by 17.5% during the 2nd quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock valued at $372,336,000 after purchasing an additional 661,542 shares during the last quarter. 65.00% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Intercept Pharmaceuticals Inc (ICPT) Insider Sells 2,000 Shares of Stock” was first posted by Zolmax and is the sole property of of Zolmax. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://zolmax.com/investing/insider-selling-intercept-pharmaceuticals-inc-icpt-insider-sells-2000-shares-of-stock-2/2919830.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

See Also: What does the Dow Jones Industrial Average (DJIA) measure?

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Vanguard Energy ETF  Announces Quarterly Dividend of $0.67
Vanguard Energy ETF Announces Quarterly Dividend of $0.67
Elbit Systems Ltd  to Issue Quarterly Dividend of $0.44
Elbit Systems Ltd to Issue Quarterly Dividend of $0.44
SDL plc  to Issue Dividend Increase – GBX 7 Per Share
SDL plc to Issue Dividend Increase – GBX 7 Per Share
Analysts Expect Avery Dennison Corp  Will Announce Quarterly Sales of $1.75 Billion
Analysts Expect Avery Dennison Corp Will Announce Quarterly Sales of $1.75 Billion
Equities Research Analysts’ Updated EPS Estimates for March, 20th
Equities Research Analysts’ Updated EPS Estimates for March, 20th
ERSTE GRP BK A/S  & GRUPO FINANCIER/ADR  Head to Head Comparison
ERSTE GRP BK A/S & GRUPO FINANCIER/ADR Head to Head Comparison


Leave a Reply

 
© 2006-2019 Zolmax.